Apidra Increased CV Events Likely Due To Baseline Imbalance, FDA Concludes
This article was originally published in Pharmaceutical Approvals Monthly
The higher incidence of cardiovascular events seen with Sanofi-Aventis’ Apidra in patients with type 1 diabetes appears to have been a result of baseline imbalances, NDA review documents suggest.
You may also be interested in...
Novo Nordisk and Aradigm may focus on type 2 diabetes only for their AERx iDMS inhaled insulin system NN1998 following disappointing glucose suppression results in a Phase III type 1 diabetes trial.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011